Mazdutide
Also known as · IBI362 · LY3305677 · OXM analogue
Overview
An oxyntomodulin-derived dual agonist developed primarily in Chinese Phase 3 programmes for obesity and type 2 diabetes, with a glucagon component intended to increase energy expenditure.
Research profile · for clinicians
Based on research: published Phase 2 and Phase 3 data in Asian populations. Studied for weight loss, glycaemic control, hepatic fat, and uric-acid reduction.
Mechanism of action
Mimics native oxyntomodulin, engaging both incretin and glucagon receptors to combine appetite suppression with increased thermogenesis and hepatic fat mobilisation.
Research record
- [01]GLORY-1 Phase 3: ≈ 14% weight reduction at 48 weeks on 6 mg.
- [02]Phase 2 diabetes data showing HbA1c reduction alongside weight loss.
Selected references
Mazdutide in Chinese adults with obesity (GLORY-1)
N. Engl. J. Med., 2025
Research deep dive
Every cited study, explained
Plain-language walkthroughs of each reference, with direct PubMed links and dosing-literature context.